A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment

Trial Profile

A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 24 Jun 2015 Planned End Date changed from 1 Jun 2014 to 1 Feb 2018 as reported by ClinicalTrials.gov.
    • 09 Apr 2014 Preliminary results after 36 weeks of treatment presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top